Movement Disorders最新文献

英文中文

Molecular‐Informed Network Analysis Unveils Fatigue‐Related Functional Connectivity in Parkinson's Disease

IF 8.6 1区医学 Q1 CLINICAL NEUROLOGY

Movement Disorders

Pub Date : 2025-04-22 DOI: 10.1002/mds.30214

Ilaria Antonella Di Vico, Manuela Moretto, Agnese Tamanti, Giovanni Tomelleri, Giulia Burati, Daniel Martins, Ottavia Dipasquale, Mattia Veronese, Alessandra Bertoldo, Elisa Menini, Angela Sandri, Sarah Ottaviani, Francesca Benedetta Pizzini, Michele Tinazzi, Marco Castellaro

BackgroundFatigue in Parkinson's disease (PD) is a prevalent and debilitating non‐motor symptom. Despite its significant impact on quality of life, the underlying neurochemical and network‐based mechanisms remain poorly understood.ObjectivesThis observational study applied a multimodal imaging approach to explore potential links between the functional connectivity of neurotransmitter‐specific circuits and fatigue in a sample of patients with PD.MethodsWe acquired resting‐state functional magnetic resonance imaging data in 35 patients with PD including 18 with clinically significant fatigue and 17 without. We applied the receptor‐enriched analysis of functional connectivity by targets (REACT) pipeline to derive patients' specific molecularly enriched networks informed by the spatial distribution of the dopamine, noradrenaline, serotonin transporters, and metabotropic glutamate 5 receptors as assessed using molecular imaging data in independent samples of healthy controls. We then conducted whole‐brain analyses inspecting both categorical differences between groups of patients with and without clinically significant fatigue, and associations exploring the full within‐sample variation in symptom ratings.ResultsWe found a significant decrease in noradrenaline‐enriched and glutamate‐enriched functional connectivity in key regions, belonging to the sensorimotor, salience, and default mode network, with increasing fatigue severity. Notably, noradrenaline‐enriched functional connectivity reductions were widespread, while glutamate‐enriched functional connectivity reductions were more restricted to the supplementary motor area. No significant relationships between fatigue and dopamine or serotonin‐enriched functional connectivity were found.ConclusionsThese findings offer supportive evidence for the putative involvement of the noradrenaline and glutamate systems in the genesis of fatigue in PD, opening new directions for treatment development exploring these neurochemical systems. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

背景帕金森病（PD）患者的疲劳是一种普遍存在且使人衰弱的非运动症状。这项观察性研究采用多模态成像方法，在帕金森病患者样本中探索神经递质特异性回路的功能连通性与疲劳之间的潜在联系。方法我们获取了35名帕金森病患者的静息态功能磁共振成像数据，其中18名患者有临床明显疲劳，17名患者无疲劳。我们应用目标功能连接受体富集分析（REACT）管道，根据健康对照独立样本中分子成像数据评估的多巴胺、去甲肾上腺素、5-羟色胺转运体和代谢谷氨酸 5 受体的空间分布，得出患者的特定分子富集网络。然后，我们进行了全脑分析，既检查了有临床显著疲劳和无临床显著疲劳患者组之间的分类差异，也探讨了症状评级在样本内的全面变化。结果我们发现，随着疲劳严重程度的增加，在属于感觉运动、显著性和默认模式网络的关键区域，富含去甲肾上腺素和富含谷氨酸的功能连接显著减少。值得注意的是，去甲肾上腺素富集的功能连接性降低是广泛的，而谷氨酸富集的功能连接性降低则更多地局限于辅助运动区。结论这些发现为去甲肾上腺素和谷氨酸系统可能参与帕金森病疲劳的成因提供了支持性证据，为探索这些神经化学系统的治疗发展开辟了新的方向。© 2025 作者。运动障碍》由 Wiley Periodicals LLC 代表国际帕金森和运动障碍协会出版。

{"title":"Molecular‐Informed Network Analysis Unveils Fatigue‐Related Functional Connectivity in Parkinson's Disease","authors":"Ilaria Antonella Di Vico, Manuela Moretto, Agnese Tamanti, Giovanni Tomelleri, Giulia Burati, Daniel Martins, Ottavia Dipasquale, Mattia Veronese, Alessandra Bertoldo, Elisa Menini, Angela Sandri, Sarah Ottaviani, Francesca Benedetta Pizzini, Michele Tinazzi, Marco Castellaro","doi":"10.1002/mds.30214","DOIUrl":"https://doi.org/10.1002/mds.30214","url":null,"abstract":"BackgroundFatigue in Parkinson's disease (PD) is a prevalent and debilitating non‐motor symptom. Despite its significant impact on quality of life, the underlying neurochemical and network‐based mechanisms remain poorly understood.ObjectivesThis observational study applied a multimodal imaging approach to explore potential links between the functional connectivity of neurotransmitter‐specific circuits and fatigue in a sample of patients with PD.MethodsWe acquired resting‐state functional magnetic resonance imaging data in 35 patients with PD including 18 with clinically significant fatigue and 17 without. We applied the receptor‐enriched analysis of functional connectivity by targets (REACT) pipeline to derive patients' specific molecularly enriched networks informed by the spatial distribution of the dopamine, noradrenaline, serotonin transporters, and metabotropic glutamate 5 receptors as assessed using molecular imaging data in independent samples of healthy controls. We then conducted whole‐brain analyses inspecting both categorical differences between groups of patients with and without clinically significant fatigue, and associations exploring the full within‐sample variation in symptom ratings.ResultsWe found a significant decrease in noradrenaline‐enriched and glutamate‐enriched functional connectivity in key regions, belonging to the sensorimotor, salience, and default mode network, with increasing fatigue severity. Notably, noradrenaline‐enriched functional connectivity reductions were widespread, while glutamate‐enriched functional connectivity reductions were more restricted to the supplementary motor area. No significant relationships between fatigue and dopamine or serotonin‐enriched functional connectivity were found.ConclusionsThese findings offer supportive evidence for the putative involvement of the noradrenaline and glutamate systems in the genesis of fatigue in PD, opening new directions for treatment development exploring these neurochemical systems. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"17 1","pages":""},"PeriodicalIF":8.6,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143862205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

In Memoriam Nir Giladi, MD (1955–2024)

IF 8.6 1区医学 Q1 CLINICAL NEUROLOGY

Movement Disorders

Pub Date : 2025-04-22 DOI: 10.1002/mds.30213

Serge Przedborski, Bastiaan R. Bloem, Vladimir S. Kostic

引用次数: 0

Validation of the International Parkinson and Movement Disorder Society Non‐Motor Symptoms Questionnaire (MDS‐NMS‐Q)

IF 8.6 1区医学 Q1 CLINICAL NEUROLOGY

Movement Disorders

Pub Date : 2025-04-19 DOI: 10.1002/mds.30202

Daniel Weintraub, Kallol Ray Chaudhuri, Anette Schrag, Pablo Martinez‐Martin, Alexandra Rizos, Eugenia Mamikonyan, Julia Gallagher, Izabelle Schoen, Juliet Staunton, Marta Pereira Fernandes, Carmen Rodriguez‐Blazquez

BackgroundThe Movement Disorder Society Non‐Motor Rating Scale (MDS‐NMS) assesses severity and frequency of non‐motor symptoms (NMS) in Parkinson's disease (PD) and is rater‐administered. The MDS‐NMS Questionnaire (MDS‐NMS‐Q), developed as a briefer (i.e., assessing symptom severity only), self‐completed version of the MDS‐NMS, is also a 13‐domain, 52‐symptom instrument with a separate non‐motor fluctuations (NMFs) section.ObjectiveThe goal was to validate the MDS‐NMS‐Q versus the MDS‐NMS.MethodsA cross‐sectional, multi‐site, international study was conducted with idiopathic PD patients. After completing the self‐administered MDS‐NMS‐Q unsupervised, patients were assessed with the rater‐administered MDS‐NMS.ResultsThe cohort consisted of 199 PD patients (mean age [±standard deviation (SD)] = 67.19 [±9.95] years; mean age at PD diagnosis [±SD] = 59.27 [±9.54] years); median Hoehn and Yahr stage = 2. Data quality was satisfactory for all 13 MDS‐NMS‐Q domains. There were no floor or ceiling effects for the total score; individual domains had no appreciable ceiling effects, but variable floor effects (5.0%–71.4%). Internal consistency for most domains was satisfactory, except for the impulse control domain (Cronbach's α ≥0.75 for 10/13 domains). Correlation and concordance between MDS‐NMS‐Q and MDS‐NMS total scores were high (Spearman rank correlation coefficient = 0.86; Kendall's coefficient of concordance = 0.93).ConclusionsThe MDS‐NMS‐Q has a strong association and concordance with the MDS‐NMS at the total score and domain level. This indicates that the MDS‐NMS‐Q, allowing self‐completion and focusing only on symptom severity, is an acceptable alternative to rater administration assessing both severity and frequency. © 2025 International Parkinson and Movement Disorder Society.

{"title":"Validation of the International Parkinson and Movement Disorder Society Non‐Motor Symptoms Questionnaire (MDS‐NMS‐Q)","authors":"Daniel Weintraub, Kallol Ray Chaudhuri, Anette Schrag, Pablo Martinez‐Martin, Alexandra Rizos, Eugenia Mamikonyan, Julia Gallagher, Izabelle Schoen, Juliet Staunton, Marta Pereira Fernandes, Carmen Rodriguez‐Blazquez","doi":"10.1002/mds.30202","DOIUrl":"https://doi.org/10.1002/mds.30202","url":null,"abstract":"BackgroundThe Movement Disorder Society Non‐Motor Rating Scale (MDS‐NMS) assesses severity and frequency of non‐motor symptoms (NMS) in Parkinson's disease (PD) and is rater‐administered. The MDS‐NMS Questionnaire (MDS‐NMS‐Q), developed as a briefer (i.e., assessing symptom severity only), self‐completed version of the MDS‐NMS, is also a 13‐domain, 52‐symptom instrument with a separate non‐motor fluctuations (NMFs) section.ObjectiveThe goal was to validate the MDS‐NMS‐Q versus the MDS‐NMS.MethodsA cross‐sectional, multi‐site, international study was conducted with idiopathic PD patients. After completing the self‐administered MDS‐NMS‐Q unsupervised, patients were assessed with the rater‐administered MDS‐NMS.ResultsThe cohort consisted of 199 PD patients (mean age [±standard deviation (SD)] = 67.19 [±9.95] years; mean age at PD diagnosis [±SD] = 59.27 [±9.54] years); median Hoehn and Yahr stage = 2. Data quality was satisfactory for all 13 MDS‐NMS‐Q domains. There were no floor or ceiling effects for the total score; individual domains had no appreciable ceiling effects, but variable floor effects (5.0%–71.4%). Internal consistency for most domains was satisfactory, except for the impulse control domain (Cronbach's α ≥0.75 for 10/13 domains). Correlation and concordance between MDS‐NMS‐Q and MDS‐NMS total scores were high (Spearman rank correlation coefficient = 0.86; Kendall's coefficient of concordance = 0.93).ConclusionsThe MDS‐NMS‐Q has a strong association and concordance with the MDS‐NMS at the total score and domain level. This indicates that the MDS‐NMS‐Q, allowing self‐completion and focusing only on symptom severity, is an acceptable alternative to rater administration assessing both severity and frequency. © 2025 International Parkinson and Movement Disorder Society.","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"57 1","pages":""},"PeriodicalIF":8.6,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143849671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Genetic and Phenotypic Spectrum of Primary Brain Calcification in a Large Cohort from China.

IF 8.6 1区医学 Q1 CLINICAL NEUROLOGY

Movement Disorders

Pub Date : 2025-04-19 DOI: 10.1002/mds.30207

Zhiru Lin,Dehao Yang,Lebo Wang,Jiaxiang Li,Xinhui Chen,Nan Jin,Yixin Kang,Xinchen Wang,Feng Fu,Haotian Wang,Xiaosheng Zheng,Fei Xie,Zhidong Cen,Wei Luo

BACKGROUNDPrimary brain calcification (PBC) is a monogenic inherited disease characterized by calcifications in basal ganglia and other brain regions, with seven causative genes identified and highly heterogeneous genetic and phenotypic spectrum.OBJECTIVEThe objective was to update the genetic and phenotypic spectrum of PBC in a large cohort from China.METHODSFive hundred eighty-four PBC families were enrolled. Brain calcification was assessed by total calcification score (TCS). Sanger sequencing of SLC20A2 and whole-exome sequencing were performed. Variants were classified by the American College of Medical Genetics and Genomics guidelines.RESULTSEighty-eight probands were genetically diagnosed with pathogenic or likely pathogenic variants in SLC20A2 (75.86%), PDGFRB (2.30%), PDGFB (3.45%), XPR1 (3.45%), MYORG (11.49%), JAM2 (3.45%), and NAA60 (1.15%). Totally, 29 unreported variants were detected. Autosomal recessive PBC (AR-PBC) patients exhibited a higher rate of clinical symptoms compared to those with autosomal dominant PBC (AD-PBC) (100.00% vs. 55.06%, P < 0.001). In all PBC, advancing age showed associations with headache/dizziness (odds ratio [OR] = 0.97, P = 0.0241), cognitive dysfunction (OR = 1.07, P = 0.0025), and psychiatric symptoms (OR = 1.05, P = 0.0396). Regional calcification analysis showed that thalamic calcification scores were associated with cognitive impairment (OR = 1.34, P = 0.0026), followed by lenticular nucleus calcification with headache/dizziness (OR = 1.55, P = 0.0046), cerebellar hemisphere calcification with motor symptoms (OR = 1.45, P = 0.0051), and caudate nucleus calcification with psychiatric manifestations (OR = 1.2, P = 0.0351).CONCLUSIONThis large-scale Chinese cohort study demonstrates the genetic spectrum of PBC and phenotypic characteristics in genetically diagnosed PBC, and also provides genotype-imaging-symptom correlations of PBC. © 2025 International Parkinson and Movement Disorder Society.

{"title":"The Genetic and Phenotypic Spectrum of Primary Brain Calcification in a Large Cohort from China.","authors":"Zhiru Lin,Dehao Yang,Lebo Wang,Jiaxiang Li,Xinhui Chen,Nan Jin,Yixin Kang,Xinchen Wang,Feng Fu,Haotian Wang,Xiaosheng Zheng,Fei Xie,Zhidong Cen,Wei Luo","doi":"10.1002/mds.30207","DOIUrl":"https://doi.org/10.1002/mds.30207","url":null,"abstract":"BACKGROUNDPrimary brain calcification (PBC) is a monogenic inherited disease characterized by calcifications in basal ganglia and other brain regions, with seven causative genes identified and highly heterogeneous genetic and phenotypic spectrum.OBJECTIVEThe objective was to update the genetic and phenotypic spectrum of PBC in a large cohort from China.METHODSFive hundred eighty-four PBC families were enrolled. Brain calcification was assessed by total calcification score (TCS). Sanger sequencing of SLC20A2 and whole-exome sequencing were performed. Variants were classified by the American College of Medical Genetics and Genomics guidelines.RESULTSEighty-eight probands were genetically diagnosed with pathogenic or likely pathogenic variants in SLC20A2 (75.86%), PDGFRB (2.30%), PDGFB (3.45%), XPR1 (3.45%), MYORG (11.49%), JAM2 (3.45%), and NAA60 (1.15%). Totally, 29 unreported variants were detected. Autosomal recessive PBC (AR-PBC) patients exhibited a higher rate of clinical symptoms compared to those with autosomal dominant PBC (AD-PBC) (100.00% vs. 55.06%, P < 0.001). In all PBC, advancing age showed associations with headache/dizziness (odds ratio [OR] = 0.97, P = 0.0241), cognitive dysfunction (OR = 1.07, P = 0.0025), and psychiatric symptoms (OR = 1.05, P = 0.0396). Regional calcification analysis showed that thalamic calcification scores were associated with cognitive impairment (OR = 1.34, P = 0.0026), followed by lenticular nucleus calcification with headache/dizziness (OR = 1.55, P = 0.0046), cerebellar hemisphere calcification with motor symptoms (OR = 1.45, P = 0.0051), and caudate nucleus calcification with psychiatric manifestations (OR = 1.2, P = 0.0351).CONCLUSIONThis large-scale Chinese cohort study demonstrates the genetic spectrum of PBC and phenotypic characteristics in genetically diagnosed PBC, and also provides genotype-imaging-symptom correlations of PBC. © 2025 International Parkinson and Movement Disorder Society.","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"28 1","pages":""},"PeriodicalIF":8.6,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143853092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment Selection and Prioritization for the EJS ACT-PD MAMS Trial Platform.

IF 8.6 1区医学 Q1 CLINICAL NEUROLOGY

Movement Disorders

Pub Date : 2025-04-18 DOI: 10.1002/mds.30190

Cristina Gonzalez-Robles,Dilan Athauda,Thomas R Barber,Roger A Barker,David T Dexter,Susan Duty,Romy Ellis-Doyle,Sonia Gandhi,Joel Handley,Edwin Jabbari,Keith Martin,Kevin McFarthing,Georgia Mills,Heather Mortiboys,Stephen Mullin,Rebecca Petty,Esther Sammler,Paula Scurfield,Simon R W Stott,George K Tofaris,Li Wei,Caroline H Williams-Gray,Alan Wong,Marie-Louise Zeissler,Richard K Wyse,Camille B Carroll,Thomas Foltynie,Oliver Bandmann,Anthony H V Schapira,

BACKGROUNDThere are currently no disease-modifying therapies (DMTs) registered for Parkinson's disease (PD). The Edmond J. Safra Accelerating Clinical Trials in Parkinson Disease (EJS ACT-PD) initiative will expedite clinical assessment of putative DMTs through a multi-arm multistage (MAMS) trial, testing several treatments against a common placebo arm and replacing unsuccessful therapies early.OBJECTIVEThe objective of this study was to describe the treatment selection process for the EJS ACT-PD clinical trial platform.METHODSA Treatment Selection Working Group (TSWG) identified compounds using complementary strategies, such as literature search, related initiatives (Cure Parkinson's International Linked Clinical Trials [iLCT] initiative), and expert suggestions. Compounds were classified into five mechanistic subgroups (mitochondrial, lysosomal, protein, inflammation, "other"). "Go/No-Go" criteria and a scoring system covering preclinical, pharmacological, and clinical evidence were devised. Experts scored the candidates for quantitative rankings. Dossiers adapted from iLCT documents were produced for the top-ranked compounds and in turn prioritized by the TSWG. Practical and logistical considerations from the Steering Committee (SC) guided the final decision. Patient and Public Involvement and Engagement representatives provided feedback throughout the process.RESULTSA total of 293 interventions were identified, 52 of which passed the "Go/No-Go" criteria and were scored. Dossiers of the 14 top-ranked compounds were submitted to the SC. Telmisartan, terazosin, and ursodeoxycholic acid were selected as the initial interventions.CONCLUSIONSDrug selection in DMT PD MAMS trials requires consideration of scientific and practical issues. We present a robust system that can inform similar initiatives. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

{"title":"Treatment Selection and Prioritization for the EJS ACT-PD MAMS Trial Platform.","authors":"Cristina Gonzalez-Robles,Dilan Athauda,Thomas R Barber,Roger A Barker,David T Dexter,Susan Duty,Romy Ellis-Doyle,Sonia Gandhi,Joel Handley,Edwin Jabbari,Keith Martin,Kevin McFarthing,Georgia Mills,Heather Mortiboys,Stephen Mullin,Rebecca Petty,Esther Sammler,Paula Scurfield,Simon R W Stott,George K Tofaris,Li Wei,Caroline H Williams-Gray,Alan Wong,Marie-Louise Zeissler,Richard K Wyse,Camille B Carroll,Thomas Foltynie,Oliver Bandmann,Anthony H V Schapira,","doi":"10.1002/mds.30190","DOIUrl":"https://doi.org/10.1002/mds.30190","url":null,"abstract":"BACKGROUNDThere are currently no disease-modifying therapies (DMTs) registered for Parkinson's disease (PD). The Edmond J. Safra Accelerating Clinical Trials in Parkinson Disease (EJS ACT-PD) initiative will expedite clinical assessment of putative DMTs through a multi-arm multistage (MAMS) trial, testing several treatments against a common placebo arm and replacing unsuccessful therapies early.OBJECTIVEThe objective of this study was to describe the treatment selection process for the EJS ACT-PD clinical trial platform.METHODSA Treatment Selection Working Group (TSWG) identified compounds using complementary strategies, such as literature search, related initiatives (Cure Parkinson's International Linked Clinical Trials [iLCT] initiative), and expert suggestions. Compounds were classified into five mechanistic subgroups (mitochondrial, lysosomal, protein, inflammation, \"other\"). \"Go/No-Go\" criteria and a scoring system covering preclinical, pharmacological, and clinical evidence were devised. Experts scored the candidates for quantitative rankings. Dossiers adapted from iLCT documents were produced for the top-ranked compounds and in turn prioritized by the TSWG. Practical and logistical considerations from the Steering Committee (SC) guided the final decision. Patient and Public Involvement and Engagement representatives provided feedback throughout the process.RESULTSA total of 293 interventions were identified, 52 of which passed the \"Go/No-Go\" criteria and were scored. Dossiers of the 14 top-ranked compounds were submitted to the SC. Telmisartan, terazosin, and ursodeoxycholic acid were selected as the initial interventions.CONCLUSIONSDrug selection in DMT PD MAMS trials requires consideration of scientific and practical issues. We present a robust system that can inform similar initiatives. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"30 1","pages":""},"PeriodicalIF":8.6,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143849540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

April Infographic

IF 7.4 1区医学 Q1 CLINICAL NEUROLOGY

Movement Disorders

Pub Date : 2025-04-18 DOI: 10.1002/mds.29847

TDP-43 Cryptic RNAs in Perry Syndrome: Differences across Brain Regions and TDP-43 Proteinopathies

引用次数: 0

Cortical Effects of Dopamine Replacement Account for Clinical Response Variability in Parkinson's Disease 多巴胺替代物的皮层效应解释了帕金森病的临床反应变异性

IF 8.6 1区医学 Q1 CLINICAL NEUROLOGY

Movement Disorders

Pub Date : 2025-04-18 DOI: 10.1002/mds.30200

Alex I. Wiesman, Mikkel C. Vinding, Panagiota Tsitsi, Per Svenningsson, Josefine Waldthaler, Daniel Lundqvist

BackgroundIndividual variability in clinical response to dopamine replacement therapy (DRT) is a key barrier to efficacious treatment for patients with Parkinson's disease (PD). A better understanding of the neurobiological sources of such interindividual differences is necessary to personalize DRT prescribing, inform future clinical interventions, and motivate translational research.ObjectiveOne potential source of this variability is an unintended secondary activation of extra‐nigrostriatal dopamine systems by DRT, particularly in the neocortex. Our goal was to determine the clinical effects of cortical dopamine system activation by DRT in patients with PD.MethodsWe used pharmaco‐magnetoencephalography data collected from patients with PD (NPD = 17, NHC = 20) before and after DRT to map their cortical neurophysiological responses to dopaminergic pharmacotherapy. By combining these DRT response maps with normative atlases of cortical dopamine system densities, we linked the variable enhancement of rhythmic cortical activity by DRT to dopamine‐rich cortical regions and determined its clinical relevance.ResultsWe found beta‐rhythmic responses to DRT in dopamine‐rich regions of the cortex that are expressed variably across individuals. Importantly, patients who exhibited a larger dopaminergic beta cortical enhancement showed a smaller clinical improvement from DRT, indicating a potential source of individual variability in medication response for patients with PD.ConclusionsWe conclude that these findings inform our understanding of the dopaminergic basis of neurophysiological variability often seen in patients with PD, and indicate that our methodological approach may be useful for data‐driven contextualization of medication effects on cortical neurophysiology in future research and clinical applications. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

{"title":"Cortical Effects of Dopamine Replacement Account for Clinical Response Variability in Parkinson's Disease","authors":"Alex I. Wiesman, Mikkel C. Vinding, Panagiota Tsitsi, Per Svenningsson, Josefine Waldthaler, Daniel Lundqvist","doi":"10.1002/mds.30200","DOIUrl":"https://doi.org/10.1002/mds.30200","url":null,"abstract":"BackgroundIndividual variability in clinical response to dopamine replacement therapy (DRT) is a key barrier to efficacious treatment for patients with Parkinson's disease (PD). A better understanding of the neurobiological sources of such interindividual differences is necessary to personalize DRT prescribing, inform future clinical interventions, and motivate translational research.ObjectiveOne potential source of this variability is an unintended secondary activation of extra‐nigrostriatal dopamine systems by DRT, particularly in the neocortex. Our goal was to determine the clinical effects of cortical dopamine system activation by DRT in patients with PD.MethodsWe used pharmaco‐magnetoencephalography data collected from patients with PD (NPD = 17, NHC = 20) before and after DRT to map their cortical neurophysiological responses to dopaminergic pharmacotherapy. By combining these DRT response maps with normative atlases of cortical dopamine system densities, we linked the variable enhancement of rhythmic cortical activity by DRT to dopamine‐rich cortical regions and determined its clinical relevance.ResultsWe found beta‐rhythmic responses to DRT in dopamine‐rich regions of the cortex that are expressed variably across individuals. Importantly, patients who exhibited a larger dopaminergic beta cortical enhancement showed a smaller clinical improvement from DRT, indicating a potential source of individual variability in medication response for patients with PD.ConclusionsWe conclude that these findings inform our understanding of the dopaminergic basis of neurophysiological variability often seen in patients with PD, and indicate that our methodological approach may be useful for data‐driven contextualization of medication effects on cortical neurophysiology in future research and clinical applications. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"32 1","pages":""},"PeriodicalIF":8.6,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143849646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Movement Disorders: Volume 40, Number 4, April 2025

IF 7.4 1区医学 Q1 CLINICAL NEUROLOGY

Movement Disorders

Pub Date : 2025-04-18 DOI: 10.1002/mds.30204

引用次数: 0

Transcutaneous Tibial Nerve Stimulation for Overactive Bladder Symptoms in Parkinson's Disease: Results from a Phase II Randomized Control Trial (STRIPE).

IF 8.6 1区医学 Q1 CLINICAL NEUROLOGY

Movement Disorders

Pub Date : 2025-04-17 DOI: 10.1002/mds.30186

Matthew D Smith,Gabriella E Portlock,Anisha Cullen,Anahita Nodehi,Marcus J Drake,Yoav Ben-Shlomo,Emily J Henderson

BACKGROUNDLower urinary tract symptoms (LUTS) are common Parkinson's disease (PD), causing great impact.OBJECTIVEThe goal was to undertake a phase II randomized control trial of transcutaneous tibial nerve stimulation (TTNS) delivered by Geko device for LUTS related to overactive bladder (OAB) in PD, an easy to use of the shelf solution.METHODSParticipants were randomized to active/sham stimulation. Primary outcome measure was the International Consultation on Incontinence Questionnaire-Overactive Bladder score (ICIQ-OAB) at 12 weeks.RESULTSA total of 148 participants were allocated to active (73) and sham arms (75). No difference was seen between arms (coefficient, 0.48; 95% CI, -0.2 to 1.2; P = 0.17), although both active and sham showed improvements over baseline. Pain was the most common adverse event.CONCLUSIONNo difference was seen between active and sham arms. Symptom improvements seen in both groups are consistent with a placebo effect, however, we cannot exclude a biological effect from the sham intervention. Although negative, this result should be taken only in context of Geko use rather TTNS in general. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

{"title":"Transcutaneous Tibial Nerve Stimulation for Overactive Bladder Symptoms in Parkinson's Disease: Results from a Phase II Randomized Control Trial (STRIPE).","authors":"Matthew D Smith,Gabriella E Portlock,Anisha Cullen,Anahita Nodehi,Marcus J Drake,Yoav Ben-Shlomo,Emily J Henderson","doi":"10.1002/mds.30186","DOIUrl":"https://doi.org/10.1002/mds.30186","url":null,"abstract":"BACKGROUNDLower urinary tract symptoms (LUTS) are common Parkinson's disease (PD), causing great impact.OBJECTIVEThe goal was to undertake a phase II randomized control trial of transcutaneous tibial nerve stimulation (TTNS) delivered by Geko device for LUTS related to overactive bladder (OAB) in PD, an easy to use of the shelf solution.METHODSParticipants were randomized to active/sham stimulation. Primary outcome measure was the International Consultation on Incontinence Questionnaire-Overactive Bladder score (ICIQ-OAB) at 12 weeks.RESULTSA total of 148 participants were allocated to active (73) and sham arms (75). No difference was seen between arms (coefficient, 0.48; 95% CI, -0.2 to 1.2; P = 0.17), although both active and sham showed improvements over baseline. Pain was the most common adverse event.CONCLUSIONNo difference was seen between active and sham arms. Symptom improvements seen in both groups are consistent with a placebo effect, however, we cannot exclude a biological effect from the sham intervention. Although negative, this result should be taken only in context of Geko use rather TTNS in general. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"6 1","pages":""},"PeriodicalIF":8.6,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143846382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and Safety of Magnetic Resonance-Guided Focused Ultrasound Thalamotomy in Essential Tremor: A Systematic Review and Metanalysis.

IF 8.6 1区医学 Q1 CLINICAL NEUROLOGY

Movement Disorders

Pub Date : 2025-04-17 DOI: 10.1002/mds.30188

Alyssa Shiramba,Steven Lane,Nicola Ray,Tom Gilbertson,Rajesha Srinivasaiah,Jay Panicker,Mark Radon,Jibril Osman-Farah,Antonella Macerollo

BACKGROUNDMagnetic resonance-guided focused ultrasound (MRgFUS) is an established surgical treatment for essential tremor, providing tremor relief without the need for an incision or general anesthesia. Meta-analyses have been limited in their exploration of the durability of the treatment effect.OBJECTIVESThe study aimed to assess the treatment effect and safety of this procedure over time. Different to other meta-analyses, this study assessed the durability of efficacy over time from 1 month to 5 years follow-up. Investigating the recurrence of tremor was an important target of this work.METHODSA systematic search of the literature utilizing set search criteria was conducted with the PubMed, Scopus, Web of Science, and Cochrane library databases, in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Data analysis was conducted in R, utilizing a random-effects model for meta-analysis and a mixed-effects model for meta-regression.RESULTSForty-five studies met the inclusion criteria, of which 42 were included in the analyses. Significant changes in hand tremor, total tremor, disability scores, and quality of life scores were demonstrated across the time points investigated, the pooled standardized mean differences being -2.36 (P < 0.0001), -2.08 (P < 0.0001), -2.85 (P < 0.0001), and -1.41 (P < 0.0001) 1 year post-operation. Sensory symptoms and unsteadiness adverse events were frequently observed, with pooled proportions of 22% (95% CI 15%; 31%) and 23% (95% CI 16%; 31%) 1 month post-MRgFUS.CONCLUSIONAlthough the procedure demonstrated efficacy and safety across the studies evaluated, meta-regression analysis suggests a decrease in treatment effect over time that requires further investigation. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

{"title":"Efficacy and Safety of Magnetic Resonance-Guided Focused Ultrasound Thalamotomy in Essential Tremor: A Systematic Review and Metanalysis.","authors":"Alyssa Shiramba,Steven Lane,Nicola Ray,Tom Gilbertson,Rajesha Srinivasaiah,Jay Panicker,Mark Radon,Jibril Osman-Farah,Antonella Macerollo","doi":"10.1002/mds.30188","DOIUrl":"https://doi.org/10.1002/mds.30188","url":null,"abstract":"BACKGROUNDMagnetic resonance-guided focused ultrasound (MRgFUS) is an established surgical treatment for essential tremor, providing tremor relief without the need for an incision or general anesthesia. Meta-analyses have been limited in their exploration of the durability of the treatment effect.OBJECTIVESThe study aimed to assess the treatment effect and safety of this procedure over time. Different to other meta-analyses, this study assessed the durability of efficacy over time from 1 month to 5 years follow-up. Investigating the recurrence of tremor was an important target of this work.METHODSA systematic search of the literature utilizing set search criteria was conducted with the PubMed, Scopus, Web of Science, and Cochrane library databases, in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Data analysis was conducted in R, utilizing a random-effects model for meta-analysis and a mixed-effects model for meta-regression.RESULTSForty-five studies met the inclusion criteria, of which 42 were included in the analyses. Significant changes in hand tremor, total tremor, disability scores, and quality of life scores were demonstrated across the time points investigated, the pooled standardized mean differences being -2.36 (P < 0.0001), -2.08 (P < 0.0001), -2.85 (P < 0.0001), and -1.41 (P < 0.0001) 1 year post-operation. Sensory symptoms and unsteadiness adverse events were frequently observed, with pooled proportions of 22% (95% CI 15%; 31%) and 23% (95% CI 16%; 31%) 1 month post-MRgFUS.CONCLUSIONAlthough the procedure demonstrated efficacy and safety across the studies evaluated, meta-regression analysis suggests a decrease in treatment effect over time that requires further investigation. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"8 1","pages":""},"PeriodicalIF":8.6,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143846383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Movement Disorders

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀